Asceneuron
Business Services · Switzerland · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Epfl Innovation Park Bâtiment B, Lausann...Phone Number
+41 216938242Website
www.asceneuron.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Asceneuron
Asceneuron, founded in 2012 and headquartered in Lausanne, Switzerland, discovers and develops innovative small molecules to halt and prevent key molecular events in the brain that lead to neurodegeneration. Asceneuron strives to address high unmet medical needs in neurodegenerative diseases such as orphan tauopathies, Alzheimer’s, and Parkinson’s diseases.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Asceneuron your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Asceneuron launches new products
Click to see if Asceneuron had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Asceneuron has new funding data
Earning: See what the market has to say on Asceneuron recently announced quarterly report
Check if Asceneuron has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Asceneuron, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Asceneuron
Check out if Asceneuron is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Asceneuron as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Asceneuron is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Asceneuron is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Asceneuron.
Asceneuron financials insights
Gather financial insights about Asceneuron, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$30.6M
2024
Series C
$100M
Asceneuron Tech Stack
A closer look at the technologies used by Asceneuron
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
Executive Move
Board of Directors
Lateral Move
Executive Move
New Hire
Executive Move
Asceneuron News & Media
Asceneuron Secures $100 Million Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases
Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. Funds will be...Novo Holdings leads $100 million Series C financing of Asceneuron to advance groundbreaking therapy for Alzheimer's disease
Funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical development for the treatment of Alzheimer's disease Alzheimer's disease is an area of very high unmet medical need with a lack of oral disease modifying therapies Naveed Siddiqi,...Asceneuron Joins Critical Path for Alzheimer's Disease Consortium
Consortium brings together industry, academic, and regulatory experts to advance research and bridge gaps in drug development targeting Alzheimer's disease Asceneuron to contribute its expertise in neurodegenerative disease to advance biomarkers for drug development in Alzheimer's disease...Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases
Significant appointments of industry and academic experts to support Phase II development of ASN51 in Alzheimer's disease LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Asceneuron
Sign Up For FreeTo access detailed company insights
Asceneuron, founded in 2012 and headquartered in Lausanne, Switzerland, discovers and develops innovative small molecules to halt and prevent key molecular events in the brain that lead to neurodegeneration. Asceneuron strives to address high unmet medical needs in neurodegenerative diseases such as orphan tauopathies, Alzheimer’s, and Parkinson’s... Read More
